Boehringer Ingelheim has bought exclusive rights to an oncology target discovered by Oxford BioTherapeutics and its proteomic database.

oxford_biotherapeutics_boehringer_ingelheim_immunoOxford BioTherapeutics is a Biotech in Milton Park (near Oxford, UK), developing immunotherapies for cancer with antibody-drug conjugates (ADC) – a strategy to combine the specificity of antibodies to a toxic agent that can be delivered to a cancerous cell.

It relies on its proprietary OGAP platform, a cancer proteome database that integrates clinical, experimental and protein expression data. This allows them to discover potential immuno-oncology targets, especially cell surface proteins.

ADVERTISEMENT

oxford_biotherapeutics_leukemia_breast_cancer

The current pipeline of Oxford Biotherapeutics. (Source: Oxford BioTherapeutics)

Now, Boehringer Ingelheim has exercised its option to buy a specific drug target from OGAP’s results. Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target.

Oxford BioTherapeutics will receive development and regulatory milestone payments, and royalties on any future product sales. But neither the target or the sum received by Oxford BioTherapeutics were disclosed.

This is the result of a collaboration established in 2013 between the 2 companies, for target discovery and validation. Boeheringer Ingelheim had already bought one other target back in January 2015 – for which details are also undisclosed.

oxford_biotherapeutics_antibody_development_arming

Current partnerships of Oxford BioTherapeutics.

Besides Boehringer Ingelheim, Oxford Biotherapeutics also has an ongoing collaboration with the Menarini group (Italy) for therapeutic development.

Covered by the deal are candidates like OBT357, for acute myeloid leukemia (AML), and OX002, an antibody-drug conjugate targeting a protein highly expressed in triple negative breast cancer.

This renewed interest by Boehringer Ingelheim is certainly an useful validation of the drug discovery strategy of Oxford Biotherapeutics.

Previous post

Very promising Results for Resistant Lung Cancer

Next post

Who are France's Young Innovators in Biotech and Medicine this year?

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.